Skip to content
Screener

Establishment Labs ESTA Stock-Based Comp

Stock-Based Comp at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$458M+11.7%
AbbVie logo
AbbVieABBV
$444M+8.3%
IAR
Integra LifeSciencesIART
$5.84M+10.4%
Artivion logo
ArtivionAORT
$8.16M+33.4%
Globus Medical logo
Globus MedicalGMED
$13.38M-1.7%
Orthofix Medical Inc. logo
Orthofix Medical Inc.OFIX
$7.74M-1.1%

Other financials

Income statement

See full
Revenue$67.5M+31.7%
Gross profit$47.7M+35.3%
Operating income-$4.3M+69.6%
Net income-$11.7M+29.2%
EPS (diluted)-$0.39+31.6%

Balance sheet

See full
Cash & equivalents$71.2M+30.2%
Total debt$263.7M+14.1%
Total equity$21.6M-5.1%
Total assets$351.9M+6.8%

Cash flow

See full
Operating cash flow-$16.6M+11.5%
CapEx$3.7M+125%
Free cash flow-$20.3M+0.6%

Valuation

See full
Market cap$2.24B+130%
Enterprise value$2.43B+111%
P/S9.1×+3.6×

Profitability

See full
Gross margin70.5%+3.3pp
Operating margin-7.6%-3.4pp
Net margin-15.8%-6.4pp
FCF margin-16.9%-6.4pp

Returns & leverage

See full
Return on equity-175.3%-43.4pp
Debt / equity12.2×+2.1×
Current ratio3.8×+1.0×

Where this comes from

Reported directly by Establishment Labs in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The source filing: Establishment Labs’s 10-Q, filed August 7, 2026.

Filed
Aug 7, 2026, 4:06 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001688757-26-000050
Line itemSix Months Ended June 30, 2026Six Months Ended June 30, 2025
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization4,8994,690
Provision (recoveries) for credit losses(214)1,964
Share-based compensation6,2355,827
Loss (gain) from disposal of property and equipment113(8)
Unrealized foreign currency loss (gain), net2,675(9,481)
Amortization of right-to-use asset461472
Non-cash loss on contract termination543

Item 1. Financial Statements - Unaudited

FAQ

What is Establishment Labs's stock-based comp?
Establishment Labs (ESTA) reported stock-based comp of $3.23M in Q2 2026.
How has Establishment Labs's stock-based comp changed year-over-year?
Establishment Labs's stock-based comp decreased by 4.7% year-over-year, from $3.39M to $3.23M.
What is the long-term trend for Establishment Labs's stock-based comp?
Over 4 years (2021 to 2025), Establishment Labs's stock-based comp has grown at a 2.3% compound annual growth rate (CAGR), from $10.41M to $11.42M.
What does stock-based comp mean?
Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.

Ask your AI about Establishment Labs's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude